<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
DATE OF REPORT - FEBRUARY 18, 1998
(Date of earliest event reported)
ALKERMES, INC.
(Exact name of Registrant as specified in its charter)
PENNSYLVANIA 0-19267 23-2472830
(State of incorporation) (Commission file number) (IRS employer
identification
number)
64 SIDNEY STREET, CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices, zip code)
AREA CODE (617) 494-0171
(Telephone number)
<PAGE> 2
ITEM 5. OTHER INFORMATION.
On February 18, 1998, the Company issued a press release, a copy of which
is attached as Exhibit 99 to this Current Report on Form 8-K.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99 Press Release, dated February 18, 1998
2
<PAGE> 3
SIGNATURES
Pursuant to requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Dated: February 19, 1998 Alkermes, Inc.
By: /s/ Michael J. Landine
---------------------------------
Michael J. Landine
Senior Vice President and Chief
Financial Officer
3
<PAGE> 4
ALKERMES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit No. Exhibit
- ----------- -------
<S> <C>
99 Press Release, dated February 18, 1998
</TABLE>
4
<PAGE> 1
NEWS RELEASE
ALKERMES
FOR IMMEDIATE RELEASE
- ---------------------
Richard F. Pops
Chief Executive Officer
64 Sidney Street
Cambridge, MA 02139
(617)494-0171
Cambridge, MA, February 18, 1998. Alkermes, Inc. (the "Company") (NASDAQ: ALKS)
announced today that it intends, subject to market and other conditions, to
raise $100 million (excluding the proceeds of the over-allotment option, if
any) through a private offering of convertible exchangeable preferred stock
within the United States.
The convertible exchangeable preferred stock will be offered through initial
purchasers in the United States only to qualified institutional buyers in
reliance on Rule 144A under the Securities Act of 1933, as amended (the
"Securities Act") and to a limited number of institutional "accredited
investors" as defined in the Securities Act.
The Company stated that it intends to use the proceeds of the offering for the
funding of preclinical testing and clinical trials and for other research and
development activities, manufacturing facilities and equipment, working
capital, and other corporate purposes. The Company may also use a portion of
its available funds for acquisitions, although no such acquisitions are
currently contemplated.
The convertible exchangeable preferred stock is expected to be convertible into
shares of common stock and exchangeable at the option of the Company for
convertible subordinated debentures of the Company. No other terms were
disclosed.
THE SECURITIES TO BE OFFERED WILL NOT BE REGISTERED UNDER THE SECURITIES ACT,
OR ANY STATE SECURITIES LAWS AND UNLESS SO REGISTERED, MAY NOT BE OFFERED OR
SOLD IN THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A
TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND APPLICABLE STATE SECURITIES LAWS.
